Clinical Scorecard: Antimicrobial Resistance in Urosepsis: Findings from the Global Prevalence of Infections in Urology (GPIU) Study Conducted Between 2003 and 2013

At a Glance

Key Highlights

• Urosepsis accounts for 25.4% of HAUTIs and has high associated mortality rates (severe sepsis: 28%, septic shock: 41%).
• Antimicrobial resistance in urosepsis pathogens is significant, with resistance assessed against 10 antibiotics and 8 antibiotic combinations.
• Pathogen spectrum and resistance profiles differ by clinical severity of urosepsis and are not fully represented by overall HAUTI data.

Guideline-Based Recommendations

Diagnosis

• Use clinical criteria including sepsis severity classification (simple urosepsis, severe urosepsis, uroseptic shock) for diagnosis.
• Obtain microbiological proof of infection via urine and blood cultures analyzed per local laboratory standards.

Management

• Administer rapid and appropriate initial intravenous antibacterial therapy targeting the identified pathogen spectrum.
• Consider local antimicrobial resistance patterns and multidrug resistance classifications (MDR, XDR, PDR) when selecting antibiotics.

Monitoring & Follow-up

• Monitor clinical severity progression from simple urosepsis to severe sepsis or septic shock.
• Track antimicrobial susceptibility and resistance trends over time to guide empirical therapy adjustments.

Risks

• High mortality risk associated with severe urosepsis and septic shock.
• Inadequate initial antimicrobial coverage increases risk of poor outcomes.
• Multidrug-resistant pathogens complicate treatment efficacy.

Patient & Prescribing Data

Hospitalized urological patients with microbiologically confirmed urosepsis from multiple global regions and hospital types.

Resistance rates to commonly used antibiotics and combinations vary; combining agents without common resistance mechanisms may improve coverage.

Clinical Best Practices

• Perform timely microbiological cultures to guide targeted antimicrobial therapy.
• Use severity classification to stratify patients and tailor management accordingly.
• Incorporate local and global antimicrobial resistance data to optimize empirical treatment choices.
• Avoid relying solely on HAUTI pathogen data to represent urosepsis resistance profiles.
• Apply standardized definitions for multidrug resistance to inform antibiotic stewardship.

References

• Sepsis and Urosepsis Mortality Data
• GPIU Study Protocol and Data Collection
• Multidrug Resistance Definitions
• Clinical Severity Classification of Urosepsis